[en] BACKGROUND AND OBJECTIVE: Serum erythropoietin (sEpo) concentration depends primarily on the rate of renal production in response to hypoxia. However, sEpo levels increase inappropriately after conditioning for autologous stem cell transplantation (ASCT) before progressively returning to adequate levels. We investigated the possible influence of erythropoietic activity on these observations. DESIGN AND METHODS: Forty patients undergoing an ASCT, 8 with bone marrow (BMT) and 32 with peripheral blood stem cells (PBSC), were separated into 3 groups. Group 1 was formed of the 8 BMT patients (median time to 1% reticulocytes: 39 days), group 2 of 16 PBSC patients with relatively slow erythroid engraftment (> or = 15 days to 1% reticulocytes, median 19 days) and group 3 of 16 PBSC patients with prompt erythroid recovery (< 15 days to 1% reticulocytes, median 13 days). Marrow erythroid activity was assessed by serum transferrin receptor levels (sTfR). Serum Epo (sEpo) levels were expressed in relation to the degree of anemia as observed/predicted (O/P) ratios of (O/P) log (sEpo). RESULTS: Serum sTfR levels decreased by more than 50% in all 3 groups after conditioning, reaching their nadir on day 7. Nadir values doubled by day 28 in group 3, day 60 in group 2, but not within 100 days in group 1. O/P sEpo ratios increased inappropriately in all 3 groups after conditioning but then declined at very differing speeds in the 3 groups. In group 1, ratios remained above 1.10 through to day 28 and above 1.00 through to day 42, before leveling off at around 1.00 thereafter. In group 2, ratios remained above 1.00 through to day 14, than decreased to a minimum of 0.89 by day 42 before returning to 1.00 by day 100. In group 3, ratios decreased to 0.84 by day 21 and remained below 0.90 thereafter. INTERPRETATION AND CONCLUSIONS: We conclude that sEpo levels are not only influenced by tissue oxygenation but also depend on the mass of erythroid precursors in the bone marrow. This may be the main explanation for the observed changes in sEpo levels during ASCT.
Disciplines :
Hematology
Author, co-author :
Beguin, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Baron, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Fillet, Georges ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Language :
English
Title :
Influence of marrow erythropoietic activity on serum erythropoietin levels after autologous hematopoietic stem cell transplantation.
Erslev AJ. Erythropoietin titers in health and disease. Semin Hematol 1991; 28:2-7.
Erslev AJ. Erythropoietin. N Engl J Med 1991; 324: 1339-44.
Beguin Y, Clemons G, Pootrakul P, Fillet G. Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood 1993; 81:1067-76.
Urabe A, Mitani K, Yoshinaga K, et al. Serum erythropoietin titers in hematological malignancies and related diseases. Int J Cell Cloning 1992; 10:333-7.
Gaines Das RE, Milne A, Rowley M, Smith EC, Cotes PM. Serum immunoreactive erythropoietin in patients with idiopathic aplastic and Fanconi's anaemias. Br J Haematol 1992; 82:601-7.
Schrezenmeier H, Noe G, Raghavachar A, Rich IN, Heimpel H, Kubanek B. Serum erythropoietin and serum transferrin receptor levels in aplastic anaemia. Br J Haematol 1994; 88:286-94.
Cazzola M, Guarnone R, Cerani P, Centenara E, Rovati A, Beguin Y. Red cell precursor mass as an independent determinant of serum erythropoietin level. Blood 1998; 91:2139-45.
Kendall RG, Cavill I, Norfolk DR. Serum erythropoietin levels during haematinic therapy. Br J Haematol 1992; 81:630-1.
Cazzola M, Beguin Y. New tools for clinical evaluation of erythron function in man. Br J Haematol 1992; 80:278-84.
Piroso E, Erslev AJ, Caro J. Inappropriate increase in erythropoietin titers during chemotherapy. Am J Hematol 1989; 32:248-54.
Birgegard G, Wide L, Simonsson B. Marked erythropoietin increase before fall in Hb after treatment with cytostatic drugs suggests mechanism other than anaemia for stimulation. Br J Haematol 1989; 72:462-6.
Abedi MR, Backman L, Bostrom L, Lindback B, Ringden O. Markedly increased serum erythropoietin levels following conditioning for allogeneic bone marrow transplantation. Bone Marrow Transplant 1990; 6:121-6.
Grace RJ, Kendall RG, Chapman C, Hartley AE, Barnard DL, Norfolk DR. Changes in serum erythropoietin levels during allogeneic bone marrow transplantation. Eur J Haematol 1991; 47:81-5.
Ireland RM, Atkinson K, Concannon A, Dodds A, Downs K, Biggs JC. Serum erythropoietin changes in autologous and allogeneic bone marrow transplant patients. Br J Haematol 1990; 76:128-34.
Lazarus HM, Goodnough LT, Goldwasser E, Long G, Arnold JL, Strohl KP. Serum erythropoietin levels and blood component therapy after autologous bone marrow transplantation: implications for erythropoietin therapy in this setting. Bone Marrow Transplant 1992; 10:71-5.
Schapira L, Antin JH, Ransil BJ, et al. Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy. Blood 1990; 76:2354-9.
Miller CB, Jones RJ, Zahurak ML, et al. Impaired erythropoietin response to anemia after bone marrow transplantation. Blood 1992; 80:2677-82.
Bosi A, Vannucchi AM, Grossi A, et al. Inadequate erythropoietin production in allogeneic bone marrow transplant patients. Haematologica 1991; 76:280-4.
Bosi A, Vannucchi AM, Grossi A, et al. Serum erythropoietin levels in patients undergoing autologous bone marrow transplantation. Bone Marrow Transplant 1991; 7:421-5.
Beguin Y, Clemons GK, Oris R, Fillet G. Circulating erythropoietin levels after bone marrow transplantation: Inappropriate response to anemia in allogeneic transplants. Blood 1991; 77:868-73.
Beguin Y, Oris R, Fillet G. Dynamics of erythropoietic recovery after bone marrow transplantation: role of marrow proliferative capacity and erythropoietin production in autologous versus allogeneic transplants. Bone Marrow Transplant 1993; 11:285-92.
Vannucchi AM, Grossi A, Bosi A, et al. Impaired erythropoietin production in mice treated with cyclosporin A. Blood 1991; 78:1615-8.
Vannucchi AM, Grossi A, Bosi A, et al. Effects of cyclosporin A on erythropoietin production by the human Hep3B hepatoma cell line. Blood 1993; 82:978-84.
Lee LG, Chen CH, Chiu LA. Thiazole orange: a new dye for reticulocyte analysis. Cytometry 1986; 7:508-17.
Huebers HA, Beguin Y, Pootrakul P, Einspahr D, Finch CA. Intact transferrin receptors in human plasma and their relation to erythropoiesis. Blood 1990; 75:102-7.
Barosi G. Inadequate erythropoietin response to anemia: definition and clinical relevance. Ann Hematol 1994; 68:215-23.
Caro J, Brown S, Miller O, Murray T, Erslev AJ. Erythropoietin levels in uremic nephric and anephric patients. J Lab Clin Med 1979; 93:449-58.
Means RT Jr, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992; 80:1639-47.
Beguin Y. Erythropoietin and the anemia of cancer. Acta Clin Belg 1996; 51:36-52.
Cotes PM, Doré CJ, Liu Yin JA, et al. Determination of serum immunoreactive erythropoietin in the investigation of erythrocytosis. N Engl J Med 1986; 315:283-7.
Fisher JW, Roh BL. Influence of alkylating agents on kidney erythropoietin production. Cancer Res 1964; 24:983-8.
Wolff M, Jelkmann W. Effects of chemotherapeutic and immunosuppressive drugs on the production of erythropoietin in human hepatoma cultures. Ann Hematol 1993; 66:27-31.
Jelkmann W, Wolff M, Fandrey J. Inhibition of erythropoietin production by cytokines and chemotherapy may contribute to the anemia in malignant diseases. Adv Exp Med Biol 1994; 345:525-30.
Youssoufian H, Longmore G, Neumann D, Yoshimura A, Lodish HF. Structure, function, and activation of the erythropoietin receptor. Blood 1993; 81:2223-36.
Bowen DT, Janowska-Wieczorek A. Serum erythropoietin following cytostatic therapy [letter]. Br J Haematol 1990; 74:372-3.
Stohlman F Jr, Brecher G. Humoral regulation of erythropoiesis. V. Relationship of plasma erythropoietin level to bone marrow activity. Proc Soc Exp Biol Med 1959; 100:40-3.
Naets JP, Wittek M. Effect of erythroid hypoplasia on utilization of erythropoietin. Nature 1965; 206:726-7.
Bozzini CE. Influence of erythroid activity of the bone marrow on the plasma disappearance of injected erythropoietin in dogs. Nature 1966; 209:1140-1.
Pick CG, Statter M, Ben-Shachar D, Youdim MB, Yanai J. Normal zinc and iron concentrations in mice after early exposure to phenobarbital. Int J Dev Neurosci 1987; 5:391-8.
Piroso E, Erslev AJ, Flaharty KK, Caro J. Erythropoietin life span in rats with hypoplastic and hyperplastic bone marrows. Am J Hematol 1991; 36:105-10.
Kampf D, Eckardt KU, Fischer HC, Schmalisch C, Ehmer B, Schostak M. Pharmacokinetics of recombinant human erythropoietin in dialysis patients after single and multiple subcutaneous administrations. Nephron 1992; 61:393-8.
Lezon C, Alippi RM, Barcelo AC, Martinez MP, Conti MI, Bozzini CE. Depression of stimulated erythropoietin production in mice with enhanced erythropoiesis. Haematologica 1995; 80:491-4.
Bergamaschi G, Recalde HH, Ponchio L, Rosti V, Cazzola M. Erythrophagocytosis increases the expression of erythroid potentiating activity mRNA in human monocyte-macrophages. Exp Hematol 1993; 21:70-3.
Erslev AJ. The effect of hemolysates on red cell production and erythropoietin release. J Lab Clin Med 1971; 78:1-7.
